Biotech Values

[zebra4o1]

Great to see some hard numbers on this phenomena: 81% of the phase III's had a lower response rate. But what a strange excercise: doing statistical checks for factors predicting sucess or failure. The answer is so obvious, but maybe not amenable to a simple statistical analysis. I wondered if they checked success rates versus the size to the company.